Protocol ID |
Title |
| EORTC 26101 |
Phase II trial exploring the sequence of bevacizumab and lomustine in patients with first recurrence of a glioblastoma |
| EORTC 26091 |
Phase II randomized trial assessing the significance of bevacizumab in recurrent grade II and III gliomas |
| EORTC 26081 |
Phase II randomized trial assessing intergroup study of radiotherapy versus temozolomide
versus radiotherapy with concomitant and adjuvant temozolomide for
patients with newly diagnosed anaplastic oligodendroglioma
or anaplastic mixed glioma with chromosomal co-deletions of 1p and
19q |
EORTC 26083
Design |
Randomized phase II of CCNU versus CCNU-dasatinib in patients with recurrent glioblastoma |
| EORTC 26082-22081 |
Phase II open-label randomized study of radiation
therapy and concurrent plus adjuvant temsirolimus (CCI-779) versus
chemo-irradiation with temozolomide in newly diagnosed glioblastoma
without methylation of the MGMT gene promoter |
EORTC 26053-22054
CATNON Intergroup Trial
(with RTOG, NCI-C, MRC, HUB)
Design |
Phase III randomized study of radiotherapy
with or without concurrent and/or adjuvant temozolomide in patients
with non-1p/19q deleted anaplastic glioma
Activated: December, 2007 |
EORTC 22042-26042
Design |
Phase II and observational study
of adjuvant high-dose radiotherapy in patients who have undergone
surgery for newly diagnosed grade II or III meningioma
Activated: 2008 |
EORTC 26062-22061,
CAN-NCIC-CE6
Design |
Phase III randomized study of short-course
radiotherapy with or without temozolomide in older patients
with newly diagnosed glioblastoma multiforme
To be activated in Europe: mid 2008 |
